amantadine has been researched along with riluzole in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 8 (53.33) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; Di, L; Huang, Y; Lin, Z; Liston, TE; Scott, DO; Troutman, MD; Umland, JP | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Vale, S | 1 |
| Hersch, SM | 1 |
| Gu, ZL; Qin, ZH; Wang, J | 1 |
| Carta, M; Cenci, MA; Fisone, G; Håkansson, K; Lundblad, M; Usiello, A | 1 |
| Bonelli, RM; Hofmann, P | 1 |
| Howland, RH | 1 |
| Egashira, N; Fujiwara, M; Harada, S; Iwasaki, K; Matsushita, M; Mishima, K; Nishimura, R; Oishi, R; Okuno, R | 1 |
| Nag, N; Storey, E; Tarlac, V | 1 |
| Armstrong, MJ; Miyasaki, JM | 1 |
| Aksinenko, AY; Bachurin, SO; Dubrovskaya, ES; Epishina, TA; Fisenko, VP; Goreva, TV; Grigoriev, VV; Lapshina, MA; Makhaeva, GF; Maleev, GV; Shevtsova, EF; Steinberg, DA; Ustyugov, AA; Veselov, IM; Vinogradova, DV; Zamoyski, VL | 1 |
5 review(s) available for amantadine and riluzole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Huntington's disease: prospects for neuroprotective therapy 10 years after the discovery of the causative genetic mutation.
Topics: Amantadine; Anti-Dyskinesia Agents; Antiparkinson Agents; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Humans; Huntingtin Protein; Huntington Disease; Nerve Degeneration; Nerve Tissue Proteins; Neuroprotective Agents; Nuclear Proteins; Point Mutation; Riluzole; Tetrabenazine; Time Factors | 2003 |
Development of novel therapies for Huntington's disease: hope and challenge.
Topics: Amantadine; Animals; Cell Transplantation; Drugs, Chinese Herbal; Humans; Huntingtin Protein; Huntington Disease; Mutation; Neostriatum; Nerve Tissue Proteins; Neuroprotective Agents; Nuclear Proteins; Riluzole | 2005 |
A systematic review of the treatment studies in Huntington's disease since 1990.
Topics: Amantadine; Antipsychotic Agents; Chorea; Depression; Humans; Huntington Disease; Neuroprotective Agents; Riluzole; Sexual Dysfunctions, Psychological; Tetrabenazine | 2007 |
Glutamate-modulating drugs & the treatment of mental disorders.
Topics: Acamprosate; Amantadine; Cycloserine; Glutamic Acid; Humans; Ketamine; Lamotrigine; Memantine; Mental Disorders; Psychotropic Drugs; Riluzole; Taurine; Triazines | 2007 |
10 other study(ies) available for amantadine and riluzole
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Species independence in brain tissue binding using brain homogenates.
Topics: Animals; Brain; Dogs; Guinea Pigs; Humans; Macaca fascicularis; Mice; Rats; Species Specificity | 2011 |
Drug treatments of levodopa-induced dyskinesias.
Topics: Amantadine; Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Levodopa; Patient Selection; Receptors, N-Methyl-D-Aspartate; Riluzole; Treatment Outcome | 1999 |
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Topics: Adenosine A2 Receptor Agonists; Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Basal Ganglia; Buspirone; Disease Models, Animal; Disease Progression; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Indoles; Levodopa; Male; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinsonian Disorders; Purines; Receptor, Adenosine A2A; Receptors, Dopamine D2; Reproducibility of Results; Riluzole; Treatment Outcome | 2005 |
Effects of glutamate-related drugs on marble-burying behavior in mice: implications for obsessive-compulsive disorder.
Topics: Acoustic Stimulation; Amantadine; Animals; Behavior, Animal; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Glutamic Acid; Male; Memantine; Mice; Mice, Inbred ICR; Motor Activity; Obsessive-Compulsive Disorder; Quinoxalines; Receptors, Glutamate; Receptors, N-Methyl-D-Aspartate; Reflex, Startle; Riluzole | 2008 |
Assessing the efficacy of specific cerebellomodulatory drugs for use as therapy for spinocerebellar ataxia type 1.
Topics: Amantadine; Animals; Ataxin-1; Ataxins; Buspirone; Disease Models, Animal; Dopamine Agents; Genotype; Hypnotics and Sedatives; Kyphosis; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Nerve Tissue Proteins; Neuroprotective Agents; Nuclear Proteins; Phenotype; Purkinje Cells; Pyridines; Riluzole; Serotonin Receptor Agonists; Spinocerebellar Ataxias; Zolpidem | 2013 |
Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology.
Topics: Adult; Amantadine; Anticonvulsants; Chorea; Evidence-Based Medicine; Humans; Huntington Disease; Riluzole | 2012 |
New Adamantane-Containing Edaravone Conjugates as Potential Neuroprotective Agents for ALS Treatments.
Topics: Adamantane; Amantadine; Amyotrophic Lateral Sclerosis; Edaravone; Humans; Neuroprotective Agents; Riluzole | 2023 |